Durvalumab/Tremelimumab Combo Explored in Lung Cancer Trial
February 5th 2016With the approval of a dual checkpoint blockade treatment in melanoma, researchers hope to have similar success in a phase III trial that combines a PD-L1 inhibitor and CTLA-4 antibody in patients with non–small cell lung cancer.
Read More
In a Crowded Field, High-Intensity Focused Ultrasound Stakes a Claim
February 2nd 2016The landscape for the patient with localized prostate cancer is filled with both new and exciting treatments. With better methods to screen, improved imaging scans to determine physical location and extent of cancer, and even active surveillance, there are many options to consider.
Read More
Genomic Classifier Refines Risk Calculation After Prostatectomy
February 1st 2016Using a genomic classifier that identifies men who are at highest risk for developing metastasis after prostatectomy and salvage radiation therapy can help clinicians distinguish which patients would benefit from more aggressive follow-up therapy, according to recent research.
Read More
Ublituximab Is Combined With Ibrutinib in High-Risk CLL Study
January 13th 2016Researchers are combining the novel CD20-targeting agent ublituximab (TG-1101) with ibrutinib to determine whether the regimen can improve outcomes in CLL, particularly for patients whose disease has high-risk features.
Read More
Prostate Cancer Guidelines Lack Molecular Test Recommendations
December 15th 2015When compared with the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, the corresponding prostate cancer guidelines fall short in one distinct characteristic—the lack of a molecular test in tissue-based platforms at this point in time.
Read More
Promising Subgroup Data Leads to Phase III Immunotherapy Study for GBM
November 21st 2015Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.
Read More
Physician Dispensing of Abiraterone and Enzalutamide for mCRPC Gains Appeal
November 7th 2015With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.
Read More
Early Docetaxel, ADT Combo Increases Survival in Advanced Prostate Cancer
August 10th 2015Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.
Read More
Improved Survival Data Seen With Abiraterone as COUGAR Trial Concludes
July 27th 2015Charles J. Ryan, MD, discusses the final survival data for pre-chemotherapy use of abiraterone from the COUGAR-AA-302 study, which demonstrated a median of 35 months for men with castration resistant prostate cancer.
Read More
Amnion/Chorion Wrap Improves Outcomes Following Robot-Assisted Prostatectomy
June 7th 2015Using an allograft made up of dehydrated human amnion/chorion membrane wrapped around the neurovascular bundle (NVB) during nerve-sparing robot-assisted radical prostatectomy improved continence and potency postsurgery, according to results of a small study.
Read More
Progress in Immunotherapy Continues, But Pseudo-Progression Is a Concern
June 5th 2015Interest is high among urologists and medical oncologists with "the explosion of checkpoint blockade inhibition studies" that initially made inroads in melanoma and non-small cell lung cancer, but is also gaining traction in bladder cancer.
Read More